Bli medlem
Bli medlem

Du är här

2022-11-09

Publication of Interim Report January – September 2022

Improved profitability and strong growth

BICO Group AB 559050-5052 (NASDAQ STOCKHOLM: BICO)

BICO is the future of life-saving treatments. We are reducing the organ shortage and speeding up drug development by providing accessible life science solutions that combine biology and technology.

JULY – SEPTEMBER 2022
(COMPARED WITH JULY – SEPTEMBER 2021)
Net sales amounted to MSEK 550.6 (315.6), which corresponds to an increase of 74% (292) compared to the corresponding period previous year.

Organic growth for the period amounted to 28% (59). Organic growth excluding currency effects for the period was 12%.
EBITDA amounted to MSEK 1.8 (-33.8), corresponding to a margin of -0.3% (-10.7).

Adjusted EBITDA amounted to MSEK 18.1 (-16.0), corresponding to a margin of 3.3% (-5.1)

Net profit/loss for the period amounted to MSEK 66.5 (-105.0), corresponding to earnings per share before and after dilution of SEK 1.04 (-1.82).

The gross margin amounted to 76.5% (73.1). The gross margin structure in the acquired companies 2021 varies depending on the product mix.

JANUARY – SEPTEMBER 2022
(COMPARED WITH JANUARY – SEPTEMBER 2021)
Net sales amounted to MSEK 1.565.4 (738.2), which corresponds to an increase of 112% (365) compared to the corresponding period previous year.

Organic growth for the period amounted to 24% (69). Organic growth excluding currency effects for the period was 10%.
EBITDA amounted to MSEK -80.6 (-58.1), corresponding to margin of -5.0% (-7.9).

Adjusted EBITDA amounted to MSEK 35.3 (-7.3), corresponding to a margin of 2.3% (-1.0).

Net profit/loss for the period amounted to MSEK 66.1 (-203.3), corresponding to earnings per share before and after dilution of SEK 1.04 (-3.62).

The gross margin amounted to 74.5% (72.2). The gross margin structure in the acquired companies 2021 varies depending on the product mix.

“Given the change in the macroeconomic environment, we have a firm focus on profitability and cash flow.”
Erik Gatenholm/ President & CEO, BICO Group AB

Q3 KEY TAKEAWAYS
· Strong product demand and high sales
· Focus on improving profitability and cash flow
· Focus on operational efficiency and acquisitions synergies
· Cost reduction program launched

INVITATION TO PRESENTATION:
Join us for a combined presentation audiocast and telephone conference with the opportunity to ask questions at 09:00 CEST today on November 9, 2022, with President & CEO Erik Gatenholm and Interim CFO Mikael Engblom. The presentation audiocast will be accessible via the following link:

Audiocast, at 09:00 am CEST:
https://ir.financialhearings.com/bico-q3-2022

To participate via telephone, please call any of the following numbers:
SE: +46 8 505 16 386
UK: +44 203 198 48 84
US: +1 412 317 6300

Pin: 6705948#

The presentation will also be available on the company’s website:
 https://bico.com/investors/financials/financial-reports-and-presentations/

For further information, please contact:
Erik Gatenholm, President & CEO, BICO Group AB
Phone: +46 73 267 0000
E-mail: eg@bico.com

Mikael Engblom, Interim CFO BICO Group AB
Phone: +46 700 918604
E-mail: me@bico.com

Åsa Hillsten, SVP Investor Relations, BICO Group AB
Phone: +46 700 818117
E-mail: ash@bico.com

About BICO
Founded in 2016, BICO (formerly CELLINK) is the world’s leading bioconvergence company,  with three business areas: Biosciences, Bioautomation, and Bioprinting. BICO reduces the organ shortage and speeds up drug development by providing accessible life science solutions that combine biology and technology, fundamentally shifting the global healthcare industry.
Using a combination of robotics, artificial intelligence, advanced genomics, and 3D bioprinting, our innovative technologies enable researchers and practitioners in the life sciences to conduct cell line development in 3D, perform high-throughput drug screening and diagnostics, and print human tissues and organs for the medical, pharmaceutical, and cosmetic industries. BICO is the future of life-saving treatments, as we enable our customers to improve people's health and lives. 
Our products are trusted by more than 3,500 laboratories, including the top 20 pharmaceutical companies. We have more than 32,000 instruments in the field in over 65 countries and have been cited in over 11,000 publications. BICO is listed on Nasdaq Stockholm under BICO. www.bico.com

This information is information that BICO Group is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2022-11-09 07:00 CET.

Attachments
ENG Q3 2022 BICO Final

Författare MFN